IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025
IGC Pharma (NYSE American: IGC) announced it will present three scientific posters at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025. The presentations will showcase the company's AI-driven innovations in Alzheimer's disease research.
The posters will highlight: 1) MINT-AD, an AI foundation model trained on 100+ global datasets for Alzheimer's risk assessment, 2) Research on using large language models to predict cognitive scores without brain scans or blood biomarkers, and 3) An AI-powered drug discovery pipeline focusing on GLP-1 and CB1 targets for Alzheimer's treatment.
IGC Pharma (NYSE American: IGC) ha annunciato che presenterà tre poster scientifici alla Conferenza Internazionale dell'Associazione Alzheimer 2025 (AAIC) che si terrà a Toronto dal 27 al 31 luglio 2025. Le presentazioni metteranno in luce le innovazioni dell'azienda basate sull'intelligenza artificiale nella ricerca sull'Alzheimer.
I poster evidenzieranno: 1) MINT-AD, un modello di intelligenza artificiale fondazionale addestrato su oltre 100 dataset globali per la valutazione del rischio di Alzheimer, 2) la ricerca sull'uso di modelli linguistici di grandi dimensioni per prevedere i punteggi cognitivi senza l'uso di scansioni cerebrali o biomarcatori ematici, e 3) una pipeline di scoperta di farmaci basata sull'IA focalizzata sui target GLP-1 e CB1 per il trattamento dell'Alzheimer.
IGC Pharma (NYSE American: IGC) anunció que presentará tres pósters científicos en la Conferencia Internacional de la Asociación de Alzheimer 2025 (AAIC) en Toronto del 27 al 31 de julio de 2025. Las presentaciones mostrarán las innovaciones impulsadas por IA de la compañía en la investigación de la enfermedad de Alzheimer.
Los pósters destacarán: 1) MINT-AD, un modelo base de IA entrenado con más de 100 conjuntos de datos globales para la evaluación del riesgo de Alzheimer, 2) investigación sobre el uso de modelos de lenguaje grandes para predecir puntuaciones cognitivas sin necesidad de escáneres cerebrales o biomarcadores sanguíneos, y 3) una línea de descubrimiento de fármacos impulsada por IA enfocada en los objetivos GLP-1 y CB1 para el tratamiento del Alzheimer.
IGC Pharma (NYSE American: IGC)는 2025년 7월 27일부터 31일까지 토론토에서 열리는 2025 알츠하이머 협회 국제 학술대회(AAIC)에서 세 편의 과학 포스터를 발표할 예정이라고 발표했습니다. 이번 발표는 알츠하이머 연구에서 회사의 AI 기반 혁신을 선보일 것입니다.
포스터는 다음 내용을 강조합니다: 1) MINT-AD, 알츠하이머 위험 평가를 위해 100개 이상의 글로벌 데이터셋으로 훈련된 AI 기초 모델, 2) 뇌 스캔이나 혈액 바이오마커 없이 인지 점수를 예측하는 대규모 언어 모델 연구, 3) 알츠하이머 치료를 위한 GLP-1 및 CB1 타깃에 중점을 둔 AI 기반 신약 발견 파이프라인.
IGC Pharma (NYSE American : IGC) a annoncé qu'elle présentera trois posters scientifiques lors de la Conférence Internationale de l'Association Alzheimer 2025 (AAIC) à Toronto, du 27 au 31 juillet 2025. Ces présentations mettront en avant les innovations de l'entreprise basées sur l'IA dans la recherche sur la maladie d'Alzheimer.
Les posters mettront en lumière : 1) MINT-AD, un modèle fondamental d'IA entraîné sur plus de 100 jeux de données mondiaux pour l'évaluation du risque d'Alzheimer, 2) des recherches sur l'utilisation de grands modèles de langage pour prédire les scores cognitifs sans imagerie cérébrale ni biomarqueurs sanguins, et 3) une chaîne de découverte de médicaments alimentée par l'IA, ciblant GLP-1 et CB1 pour le traitement de la maladie d'Alzheimer.
IGC Pharma (NYSE American: IGC) gab bekannt, dass es drei wissenschaftliche Poster auf der Alzheimer’s Association International Conference (AAIC) 2025 in Toronto vom 27. bis 31. Juli 2025 präsentieren wird. Die Präsentationen zeigen die KI-gesteuerten Innovationen des Unternehmens in der Alzheimer-Forschung.
Die Poster heben hervor: 1) MINT-AD, ein KI-Grundlagenmodell, das auf über 100 globalen Datensätzen für die Alzheimer-Risikobewertung trainiert wurde, 2) Forschung zum Einsatz großer Sprachmodelle zur Vorhersage kognitiver Werte ohne Gehirnscans oder Blut-Biomarker, und 3) eine KI-gestützte Wirkstoffentdeckungspipeline mit Fokus auf GLP-1- und CB1-Ziele zur Alzheimer-Behandlung.
- None.
- None.
- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings -
POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the presentation of three scientific posters at the 2025 Alzheimer's Association International Conference ("AAIC"), taking place July 27-31 in Toronto, Canada. The poster presentations highlight advancements in the Company's proprietary artificial intelligence ("AI") platforms designed to accelerate drug discovery and improve early detection of Alzheimer's disease, particularly in low-resource settings. IGC Pharma's team will be participating in person.
"We are excited to share our latest AI innovations at AAIC 2025, which underscore IGC's commitment to transforming Alzheimer's care and research", said Ram Mukunda, CEO of IGC Pharma. "Our cutting-edge deep learning techniques are designed to expand access to earlier diagnosis and accelerate the discovery of effective therapeutics by leveraging diverse, real-world datasets. Showcasing this research at the AAIC is a pivotal step as we establish IGC as a leader in applying AI to precision medicine in Alzheimer's, strengthening our scientific foundation and streamlining drug development."
At the AAIC 2025, IGC's team will present:
Poster Number: 108625
Title: Multimodal Interpretable Transformer for AD (MINT-AD)Highlights: The poster introduces MINT-AD, an AI foundation model being trained on over 100 globally diverse datasets to stratify Alzheimer's risk and forecast cognitive decline. Designed to empower general practitioners, MINT-AD integrates clinical, demographic, and lifestyle data to produce personalized, interpretable Alzheimer's risk assessments and predict cognitive decline. MINT-AD enables the earlier identification and intervention for over 400 million individuals globally with early disease pathology who could potentially benefit.
Poster Number: 108631
Title: MINT-AD: Early Prediction of MMSE & CSI-D Scores with AIHighlights: IGC will present research demonstrating the use of large language models ("LLM") to accurately predict Mini Mental State Exam ("MMSE") and Community Screening Instrument for Dementia ("CSI-D") cognitive scores. Crucially, these predictions are made using socioeconomic data alone, in the absence of brain scan or blood biomarker data, offering a highly scalable, accessible approach to support clinicians in predicting cognitive decline trajectories and guiding early interventions.
Poster Number: 108629
Title: AI in the Drug Discovery PipelineHighlights: This poster details IGC's hybrid in-silico and in-vitro pipeline, which utilizes AI-powered screening models to rapidly identify and optimize interactions between proprietary molecules and Alzheimer's-relevant targets, including GLP-1 and CB1. The results highlight strong predictive capabilities, demonstrating significant promise for accelerating future in vitro validation and compound optimization efforts in Alzheimer's disease discovery.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information
Rosalyn Christian/Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
When and where will IGC Pharma present at AAIC 2025?
What is IGC Pharma's MINT-AD AI platform for Alzheimer's disease?
How does IGC Pharma's AI technology predict cognitive scores?
What is IGC Pharma's approach to AI-driven drug discovery for Alzheimer's?
What are the three poster presentations IGC Pharma will showcase at AAIC 2025?
